Can prednisolone 2.5 mg once daily be discontinued?

Can Prednisolone 2.5 mg Once Daily Be Discontinued?

Yes, prednisolone 2.5 mg once daily can be discontinued, but this must be done with careful assessment of adrenal function and gradual tapering to avoid adrenal insufficiency. At this physiologic dose, the hypothalamic-pituitary-adrenal (HPA) axis may have recovered, but testing is recommended before complete withdrawal.

Key Principles for Discontinuation

Assessment Before Stopping

When patients reach a physiologic daily dose equivalent (approximately 4-6 mg prednisone, which 2.5 mg prednisolone falls below), you have two evidence-based options 1:

1. Continue gradual tapering while monitoring clinically for signs/symptoms of adrenal insufficiency
2. Test with morning serum cortisol to confirm HPA axis recovery

Morning Cortisol Testing Guidelines

If you choose to test (recommended approach), interpret the morning serum cortisol as follows 1:

• >300 nmol/L (10 μg/dL): HPA axis recovered → glucocorticoids can be stopped safely
• 150-300 nmol/L (5-10 μg/dL): Continue physiologic dose → retest in weeks to months
• <150 nmol/L (5 μg/dL): Continue physiologic dose → retest after a few months

Research supports that HPA activity is completely recovered when prednisone doses fall below 5 mg/day, with complete adrenal blockage occurring at doses above 7.5 mg/day 2. Since 2.5 mg prednisolone is well below this threshold, recovery is likely if the patient has been at this dose for sufficient time.

Tapering Strategy

Do not stop abruptly 3. The most recent joint European/American guideline recommends 1:

• From physiologic doses, taper gradually in small decrements
• Monitor for adrenal insufficiency symptoms during tapering
• If symptoms develop, temporarily increase to the most recent tolerated dose

For context, polymyalgia rheumatica guidelines suggest tapering by 1 mg every 4 weeks once in the low-dose range 4, though this applies to higher starting doses.

Critical Considerations

Duration of Prior Therapy Matters

Patients on glucocorticoids <3-4 weeks can stop without tapering regardless of dose 1. However, for long-term therapy (which 2.5 mg daily suggests), the risk of HPA suppression exists even at low doses if treatment exceeded 3 weeks at higher doses previously 5.

Disease-Specific Context

The underlying condition matters:

• If the disease is controlled and glucocorticoids are no longer needed for the primary condition, proceed with discontinuation 1
• If still treating active disease, do not test for adrenal insufficiency or attempt withdrawal 1

Adrenal Insufficiency Risk

Be aware of glucocorticoid withdrawal syndrome, which can mimic adrenal insufficiency but represents a different phenomenon 1. True adrenal insufficiency requires:

• Adequate replacement during acute stress/illness
• Patient education about emergency situations
• Consideration of endocrinology consultation for complex cases 1

Practical Algorithm

1. Confirm disease control: Ensure the underlying condition no longer requires glucocorticoid therapy
2. Check morning cortisol (8-9 AM) while still on 2.5 mg prednisolone
3. If cortisol >300 nmol/L: Taper by 0.5-1 mg every 2-4 weeks to zero
4. If cortisol 150-300 nmol/L: Continue 2.5 mg, retest in 4-8 weeks
5. If cortisol <150 nmol/L: Continue 2.5 mg, retest in 2-3 months
6. After complete discontinuation: Recheck cortisol 12 weeks later to confirm recovery 6

Common Pitfalls

• Stopping too quickly: Even at 2.5 mg, abrupt cessation risks adrenal crisis in patients with suppressed HPA axis
• Not testing before discontinuation: Assuming recovery without confirmation can be dangerous
• Ignoring withdrawal symptoms: Distinguish between glucocorticoid withdrawal syndrome (can continue tapering) and true adrenal insufficiency (requires dose increase)
• Inadequate patient education: Patients must understand stress-dose requirements if HPA axis not fully recovered

The evidence strongly supports that 2.5 mg prednisolone daily can and should be discontinued when appropriate, but only after confirming adequate adrenal function through morning cortisol testing or very gradual tapering with close clinical monitoring.